Skip to main content
search
All Posts By

admin

Regulatory Affairs NewsletterRegulatory Affairs Newsletter ArchiveUK Government Updates Regulatory Affairs NewsletterUK Government Updates Regulatory Affairs Newsletter Archive

Foot and Mouth Disease (FMD): Greece

Dear Members, The UK is restricting imports of certain products from Greece because of the presence of Foot and Mouth Disease. This will include certain animal by-products which have not been adequately processed. Due to an outbreak of FMD in Greece, the import of the following commodities is now suspended: live (including non-domestic) ruminants and porcine animals, including wild game and…
admin
March 19, 2026
Regulatory Affairs NewsletterRegulatory Affairs Newsletter ArchiveUK Government Updates Regulatory Affairs NewsletterUK Government Updates Regulatory Affairs Newsletter Archive

Update to UK Sanctions List: Russia Regime

Dear Members, please note the below updated list for UK Sanctions. Of note there are a couple of Banks listed not just individuals or companies. Today, Tuesday 17 March, the UK Government has varied 1 individual, corrected 3 entities and 1 individual and revoked (de-listed) 1 individual under the Russia sanctions regime. Varied Individual: Name Unique ID Viacheslav KANTOR RUS1127…
admin
March 19, 2026
Regulatory Affairs NewsletterRegulatory Affairs Newsletter ArchiveUK Government Updates Regulatory Affairs NewsletterUK Government Updates Regulatory Affairs Newsletter Archive

Biocides: Active substance renewal submission deadlines

Upcoming GB active substance renewal submission deadlines Apply for active substance renewal by the deadlines to keep products on the GB market. Under the GB Biocidal Products Regulation (GB BPR), active substance approvals will expire unless a renewal application is submitted to HSE at least 550 days before their expiry date. The 550-day deadlines are coming up for the following…
admin
March 19, 2026
Industry Newsletters Regulatory Affairs NewsletterIndustry Newsletters Regulatory Affairs Newsletter ArchiveRegulatory Affairs NewsletterRegulatory Affairs Newsletter Archive

TGA Software based medical device exclusion guidance

Dear Members, TGA has posted Guidance on Software based medical device exclusions for specific uses. Software-based medical device exclusions | Therapeutic Goods Administration (TGA) TGA – Guidance - Understanding the health facility management software exclusion - Guidance on when software used for the administration or management of health processes or facilities may be excluded from our regulatory requirements. View article...…
admin
March 19, 2026
Industry Newsletters Regulatory Affairs NewsletterIndustry Newsletters Regulatory Affairs Newsletter ArchiveRegulatory Affairs NewsletterRegulatory Affairs Newsletter Archive

The Digital Markets, Competition and Consumers Act 2024 (Commencement No. 3 and Transitional Provisions) Regulations 2026

Dear members, the implementation legislation below impacts the provision of alternative dispute resolution under the Digital Markets and Competition and Consumer Protection Act 2024. The Digital Markets, Competition and Consumers Act 2024 (Commencement No. 3 and Transitional Provisions) Regulations 2026 These Regulations bring into force Chapter 4 of Part 4 and Schedules 25 to 27 of the Digital Markets, Competition…
admin
March 19, 2026
Regulatory Affairs NewsletterRegulatory Affairs Newsletter ArchiveUK Government Updates Regulatory Affairs NewsletterUK Government Updates Regulatory Affairs Newsletter Archive

MHRA Updates – WC 15th March

Clinical trials for medicines: apply for approval in the UK Page summary: How to apply for a clinical trial from 28 April 2026, including eligibility, documentation and registration in a public registry. Change made: Updated link to guidance for IMP+device trials. Time updated: 9:00am, 9 March 2026 Clinical trials that include an in vitro diagnostic device Page summary: Guidance on…
admin
March 19, 2026
MedTech Europe Updates Regulatory Affairs NewsletterMedTech Europe Updates Regulatory Affairs Newsletter ArchiveRegulatory Affairs NewsletterRegulatory Affairs Newsletter Archive

Joint industry statement following EU–Switzerland agreement package

Following the recent signature of the EU–Switzerland agreement package, MedTech Europe, Swiss Medtech and SVDI have issued a joint statement welcoming the signature and highlighting the importance of updating the medical devices chapter of the Mutual Recognition Agreement (MRA) for the medical technology sector. As many of you will know, the MRA enables mutual recognition of conformity assessment procedures, allowing…
admin
March 19, 2026
Close Menu